Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hans-Joerg Fricke"'
Autor:
Paul La Rosée, Sebastian Scholl, Karin G. Schrenk, Peter Fix, Baerbel Spies-Weisshart, Hans-Joerg Fricke, Ulf Schnetzke, Andreas Hochhaus, Anita Glaser
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 140:1391-1397
Approximately, 70 % of adult patients with de novo acute myeloid leukemia (AML) achieve a complete remission (CR) while 10-20 % of AML are refractory to induction chemotherapy. Furthermore, a significant proportion of AML patients in CR will relapse
Autor:
Wolfgang Knauf, Marco Montillo, Liana Gercheva, Javier Loscertales, Toshko Lissichkov, Peter S. Klein, Raoul Herbrecht, Ilaria Del Giudice, Lothar Tremmel, Anna Marina Liberati, Martin Becker, Gerhard Postner, Gunnar Juliusson, Karlheinz Merkle, Hans Joerg Fricke, Ali Aldaoud, Françoise Huguet, Stefan Goranov
Publikováno v:
Journal of Clinical Oncology. 27:4378-4384
Purpose This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine and chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135:491-505
The role of different cytogenetic changes has been extensively evaluated in patients with acute myeloid leukemia (AML), and cytogenetic analysis of AML blasts is essential to form prognostic subgroups in order to stratify for the extent of therapy. N
Autor:
Lars-Olof Mügge, Ulrich Wedding, Claudia Theuer, Klaus Höffken, Veit Scheble, Christa Kunert, Hans-Joerg Fricke, Anita Heller, Sebastian Scholl
Publikováno v:
European Journal of Haematology. 80:208-215
Background: Nucleophosmin (NPM1) and Flt3 internal tandem duplications (Flt3-ITD mutations) represent the most frequent molecular aberrations in patients with acute myeloid leukemia (AML). While NPM1 mutations are associated with favourable prognosis
Autor:
Almuth Klippstein, B Röhrig, Ulrich Wedding, Klaus Höffken, Herbert G. Sayer, Hans-Joerg Fricke
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 132:665-671
Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are ra
Autor:
K. Bremer, P. Richter, Andreas Schwarzer, Chr. Müller, Rita Pasold, Manfred Schulze, Dietger Niederwieser, Chr. Klinkenstein, Klaus Dachselt, J. Weniger, C. Boewer, H. Arzberger, Mathias Freund, Antje Schulze, Cornelia Winkelmann, C. A. Müller, Veronika Schirmer, B. Ismer, Hans-Joerg Fricke, A. Franke, S. Hahnfeld, Michael Herold
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 132:105-112
Purpose: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced ind
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 127:48-54
Bendamustine, an alkylating agent without cross-resistance to cyclophosphamide is active in a variety of lymphoproliferative and other malignancies. In an open phase-II study we treated 23 patients with a median age of 62 years at study entry (43-86
Autor:
Baerbel Spies-Weisshart, Andreas Hochhaus, Lars-Olof Muegge, Hans-Joerg Fricke, Anne Klink, Sebastian Scholl
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2010, 90 (4), pp.473-475. ⟨10.1007/s00277-010-1027-9⟩
Annals of Hematology, Springer Verlag, 2010, 90 (4), pp.473-475. ⟨10.1007/s00277-010-1027-9⟩
International audience
Autor:
Karlheinz Merkle, Wolfgang Knauf, Ilaria Del Giudice, Javier Loscertales, Martin Becker, Marco Montillo, Stefan Goranov, Gerhard Postner, Gunnar Juliusson, Anna M. Liberati, Toshko Lissitchkov, Peter S. Klein, Hans Joerg Fricke, Liana Gercheva, Ali Aldaoud, Françoise Huguet, Raoul Herbrecht
The efficacy of bendamustine versus chlorambucil in a phase III trial of previously untreated patients with Binet stage B/C chronic lymphocytic leukaemia (CLL) was re-evaluated after a median observation time of 54 months in May 2010. Overall surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b3038e7e31a96ead4cb21f4c890d62
http://hdl.handle.net/11573/481318
http://hdl.handle.net/11573/481318
Autor:
Michael Kiehntopf, Iver Petersen, Hans Joerg Fricke, Nils Winkelmann, Ulrich Wedding, Andreas Hochhaus
Publikováno v:
Journal of cancer research and clinical oncology. 137(4)
The prevalence of elderly and comorbid patients (pts) with malignant lymphoma (ML) will steadily increase in future. Elderly patients comprise a heterogeneous population. Comprehensive geriatric assessment (CGA) is an established diagnostic tool in g